ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Article

Gilbert, Mark, Zhang, Peixin, Sloan, Andrew et al. (2018). ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) . NEURO-ONCOLOGY, 20(suppl_6), vi7-vi7. 10.1093/neuonc/noy148.024

cited authors

  • Gilbert, Mark; Zhang, Peixin; Sloan, Andrew; Aldape, Kenneth; Wu, Jing; Rogers, Lisa; Wen, Patrick; Barani, Igor; Iwamoto, Fabio; Raval, Raju; Voloshin, Alfredo; de Groot, John; Won, Minhee; Mehta, Minesh P

authors

publication date

  • November 5, 2018

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • 6.2 Cellular and gene therapies
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Immunotherapy
  • Minority Health
  • Neurosciences
  • Orphan Drug
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi7

end page

  • vi7

volume

  • 20

issue

  • suppl_6